Type 1 Neuro®bromatosis (NF1) is characterized by the formation of neuro®bromas, benign tumors composed mainly of Schwann cells, which can turn malignant to form neuro®brosarcomas. Neuro®bromin, the protein product of the Nf1 gene, is believed to act as a tumor suppressor, accelerating the conversion of the oncogene Ras to its inactive form. The absence of neuro®bromin could therefore lead to higher Ras activity in Schwann cells, resulting in uncontrolled growth through a cascade of events not yet elucidated. We describe the abnormal expression of high levels of the Kit tyrosine kinase receptor in both NF1-derived Schwann cell lines and tissue, as compared to primary Schwann cells or schwannoma-derived cells. High levels of Kit expression in the neuro®brosarcoma-derived Schwann cells correlate with a decrease in neuro®bromin expression. Using inhibitors of tyrosine kinase receptors, we found that proliferation of the neuro®brosarcoma-derived cells is dependent upon activation of a subclass of tyrosinekinase receptors. The proliferation of these cells is not dependent upon an autocrine loop involving typical Schwann cell mitogens. Finally, the proliferation of the neuro®brosarcoma-derived Schwann cells can be increased by stimulation with Kit ligand. These data implicate Kit as one of the components leading to the Schwann cell hyperplasia observed in NF1.
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Keywords: neuro®bromatosis; Schwann cells; c-kit proto-oncogene; stem cell factor; growth factors Neuro®bromatosis Type 1 (NF1) is a human genetic disorder aecting approximately one in 3000 individuals that manifests with various phenotypic features, including neuro®bromas, cafeÂ -au-lait spots, axillary freckling, Lisch nodules, optical gliomas, skeletal abnormalities and learning disabilities (Riccardi, 1991) . Neuro®bromas are benign peripheral nerve sheath tumors, which are comprised primarily of Schwann cells, but also contain ®broblasts, perineurial cells and mast cells embedded in an abundant extracellular matrix. Patients with NF1 are at risk for development of malignant Schwann cell tumors, called neuro®brosarcomas, which often arise from a preexisting neuro®broma (Ducatman et al., 1986; Halling et al., 1996) . The Nf1 gene, mutated in NF1, was identi®ed by positional cloning Viskochil et al., 1990; Wallace et al., 1990) and its protein product, neuro®bromin, was found to be expressed at highest abundance in neurons, Schwann cells and oligodendrocytes (Datson et al., 1992) . Because the Nf1 gene shares sequence homology with genes coding for Ras GTPase activating proteins Xu et al., 1990) , it was hypothesized that in the absence of functional neuro®bromin, Ras deregulation could lead to tumor formation in NF1 (Basu et al., 1992; DeClue et al., 1992) . However, introduction of activated Ras into normal Schwann cells resulted in growth arrest (Ridley et al., 1988) and Schwann cells from neuro®bromin de®cient mice exhibit activation of Ras and inhibition of cell proliferation (Kim et al., 1995) . Therefore mutation in NF1 itself cannot explain NF1-Schwann cell hyperplasia and other factors underlying the development of NFS still need to be investigated.
Stem cell factor (SCF) is a growth factor required for the development of hematopoietic stem cells, primordial germ cells and melanocytes (Williams et al., 1992) . We have previously shown that normal Schwann cells, as well as a neuro®brosarcoma (NFS)-derived cell line express SCF (Ryan et al., 1994) . The receptor for SCF is the protein product of the protooncogene kit, which belongs to the platelet-derived growth factor (PDGF) subgroup of tyrosine kinase receptors (Yarden et al., 1987) . Interestingly, Kit was not found in normal Schwann cells, but was expressed in the NFS-derived Schwann cell line, raising the possibility of an autocrine stimulated growth (Ryan et al., 1994) . Therefore, it was of interest to further investigate the role of Kit in the development of Schwann cell tumors associated with NF1. In this study, we analysed both Kit and neuro®bromin expression in primary Schwann cells, in Schwann cell lines derived from NF1-associated tumors and in a Schwann cell line derived from a sporadic schwannoma. We also investigated the possible contribution of tyrosine kinase receptor activation, in general, and Kit activation, in particular, to the hyperproliferative process leading to Schwann cell hyperplasia in NF1.
In order to show that expression of high levels of Kit is a feature speci®c for Schwann cells derived from NF1 patients, we evaluated the expression of Kit in four dierent Schwann cell lines, by Western blotting. Three of the cell lines, ST88-14, T265-2c and NF1T were derived from neuro®brosarcomas resected from patients diagnosed with NF1. The fourth cell line, called STS-26T, was isolated from an isolated grade III malignant schwannoma in an individual without NF1. Immunocytochemical analysis revealed that the overall pattern of expression for Schwann cell markers is consistent with a Schwann cell origin for each of the four tumor-derived cell lines (Ryan et al., 1994 ; Klein and De Vries, submitted for publication). Western blotting analysis con®rmed that the tumor-derived cell lines expressed signi®cant levels of CNPase (2', 3'-cyclic nucleotide 3'-phosphohydrolase) and laminin (data not shown). The ST88-14 and T265-2c cell lines displayed high levels of Kit protein compared to the STS-26T and NF1T cells (Figure 1a) . Primary rat Schwann cells showed little Kit expression. The NF1 phenotype has been linked to mutations in the Nf1 gene. Therefore we analysed the expression of neuro®bromin in the four cell lines (Figure 1b) . Human neuro®bromin appeared as a 250 kDa doublet band on Western blots. The schwannoma derived cell line, STS-26T, showed levels of neuro®bromin comparable to normal Schwann cells. The two NFS-derived Schwann cell lines expressed very low levels (ST88-14) or no detectable levels of neuro®bromin (T265-2c). Surprisingly, NF1T cells, although derived from a patient diagnosed with NF1, displayed levels of neuro®bromin comparable to cultured rat Schwann cells or to the STS-26T cell line. Thus, Schwann cell lines expressing neuro®bromin did not express appreciable levels of Kit, whereas cell lines de®cient in neuro®bromin showed high expression of Kit protein.
To evaluate the state of Kit activation in the cell lines expressing high levels of Kit, proteins were immunoprecipitated with an anti-Kit antibody, then analysed using an anti-phosphotyrosine antibody. Two proteins, a 145 kDa protein corresponding to Kit and a smaller protein of approximately 80 kDa, were immunoprecipitated from both NFS-derived Schwann cell lines (Figure 1c , lanes 1 and 2). The astroglioma cell line A172 (lane 3), which has high levels of Kit expression, was used as a positive control. When used in Western blotting analysis of whole cell lysates, the same anti-Kit antibody recognized predominantly the 80 kDa protein. Both Kit and the smaller protein immunologically related to Kit were tyrosyl-phosphorylated ( Figure 1d) . A 100 kDa phosphotyrosylated protein was also observed, but was immunoprecipitated by non-speci®c rabbit immunoglobulins as well (lane 4).
Kit expression in the NFS-derived Schwann cells was also analysed by immunocytochemistry ( Figure  2a ). ST88-14 cells, which can appear as bipolar spindleshaped cells or pleiomorphic¯attened cells, showed high levels of Kit expression throughout the cell bodies and processes. While the level of cytosolic Kit expression was relatively homogeneous within the cell population, some cells also displayed a strong nuclear staining. High expression of Kit was not only observed in vitro in the NFS-derived cell lines, but also in vivo, as revealed by immunohistochemistry of fresh tissue sections from an NF1 tumor. The tumor, identi®ed as a plexiform neuro®broma, was ®rst analysed using an antibody against the Schwann cell marker, S100. The anti-S100 antibody stained elongated, spindle shaped cells, with a morphology characteristic of the Schwann cells present in neuro®bromas (not shown). The Kit antibody had a wider spectrum of staining. In addition to staining the cell bodies and processes of the S100 reactive Schwann cell-like cells, Kit antibody also stained large round cells, which have a morphology consistent with mast cells (Figure 2b) .
Kit is present and tyrosyl-phosphorylated in the NF1-derived cell lines. If Kit is involved in the proliferation of the NFS-derived Schwann cells, then inhibition of the tyrosine kinase activity in the cells For immunoprecipitation, cells cultured in serum-free media were lysed and incubated overnight in the presence of a preformed complex of Protein A-agarose/ anti-Kit antibody (C-19, Santa-Cruz Biotechnology) at 48C. The cell lysates and the immunoprecipitated proteins were analysed by electrophoresis in a 7.5% polyacrylamide gel and transfer to a PVDF membrane (Dupong, NEN). After blocking with a 5% nonfat dry milk solution, the PVDF membrane was probed with the appropriate primary antibody (anti-Kit Ab-1 from Oncogene Science, anti-neuro®bromin from Santa Cruz Biotechnology or anti-phosphotyrosine from Transduction Laboratories). The antibody was detected using a horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence (Dupont-NEN). Primary rat Schwann cells were prepared according to Brockes and colleagues (1979) Figure 2 Immunocytochemical detection of Kit in the NFSderived Schwann cell line ST88-14 (a) and in fresh frozen sections (15 mm) of a plexiform neuro®broma (b). Cells and tissue were incubated with an anti-Kit antibody (Santa-Cruz Biotechnology) and visualized using a rhodamine-conjugated secondary antibody. Immunocytochemistry was performed as described before (Lee et al., 1996) . In the tumor, Kit is present in both large round cells, probably mast cells (arrow) and spindle-shaped, Schwann-like cells with extended processes (arrowheads). In the absence of primary antibody, cells and tissue sections showed no fluorescence. Bar is 10 mm should decrease their proliferation. The NFS-derived cell lines, ST88-14 and T265-2c, and the A172 line were cultured in the presence of increasing concentrations of tyrosine kinase inhibitors, in serum-free media. Tyrosine kinase inhibitors acting either through competitive inhibition of ATP binding (Genistein) or by competitive inhibition of substrate binding to the kinase domain (Tyrphostin A9 and Tyrphostin A25) were tested. Tyrphostin A9, a tyrosine kinase inhibitor speci®c for PDGF-like tyrosine kinase receptors, decreased the rate of NFS-derived Schwann cell proliferation in a dose-dependent manner with an ED50 of approximately 1.5 mM (Figure 3a) , close to its Ki/IC 50 (Levitzki and Gilon, 1991) . Tyrphostin A25 and Genistein, with respective ED50 of 80 mM and 25 mM, were ecient inhibitors of cell proliferation only at concentrations largely higher than their published Ki/IC 50 (Gazit et al., 1989) , probably targeting a wide range of tyrosine kinase receptors. To demonstrate that tyrosine phosphorylation was actually inhibited by the tyrosine kinase inhibitors, ST88-14 cells were collected after 3 days of treatment with the tyrosine kinase inhibitors. Proteins were then analysed by Western blotting using an anti-phosphotyrosine antibody and the lanes were scanned to evaluate the relative amounts of tyrosyl-phosphorylated proteins. We observed a general decrease in the level of tyrosine phosphorylated proteins in cells cultured in the presence of Genistein (45% decrease), Tyrphostin A9 (85% decrease) and Tyrphostin A25 (90% decrease) which could be correlated to the decrease in cell proliferation observed in the presence of these inhibitors (Figure 3d) .
Proliferation of many tumor cell lines is driven by an autocrine loop, involving activation of a growth factor receptor by its ligands expressed by the same cells. To determine if a Kit/SCF autocrine loop was responsible for the NF1 cell line proliferation, cell growth was evaluated in the presence of neutralizing antibodies to SCF (R&D systems) or to Kit (clones 1.D9.3D6, Boehringer Mannheim Corporation or K44.2, Sigma Bioscience). These antibodies have been used to interfere with SCF activity in various systems and in particular to disrupt the autocrine growth of breast carcinoma cell lines (Bleechman et al., 1993; Hines et al., 1995) . Anti-SCF antibodies (used at concentrations as high as 50 mg/ml) had no signi®cant eect on the proliferation rate of the NFS-derived Schwann cell lines grown in serum-containing or serum-free media. (Figure 4a) . Similarly, both anti-Kit antibodies (used at concentrations as high as 25 mg/ml) failed to prevent the growth of the NFS-derived cell lines (data not Figure 3 Eect of tyrosine kinase inhibitors on the proliferation of NFS-derived cell lines and the A172 glioma cell line. Cells (5000/well) were incubated in serum-free media for 3 days, in the presence of increasing amounts of Tyrphostin A9 (a), Tyrphostin A25 (b) or Genistein (c), all obtained from LC Laboratories. Cell number at 0 and 3 days was evaluated by the colorimetric MTT assay (Boehringer Mannheim Corporation). Absorbance was measured at 595 nm and growth expressed as the change in absorbance relative to untreated controls. Results were expressed as the mean+s.e. of triplicate wells (n=3 ± 5). Microscopic examination showed little if any cytotoxicity of the compounds at the doses used in these experiments. (d) ST88-14 cells treated with 5 mM Tyrphostin A9, 150 mM Tyrphostin A25 or 50 mM Genistein as described above were lysed and the proteins analysed by Western blotting using an anti-phosphotyrosine antibody. Densitometric analysis of proteins was performed using the BioRad GS-670 densitometer and expressed relative to control (cells treated with vehicle) Figure 4 Eect of anti-SCF antibodies (a) and suramin (b) on the proliferation of NFS-derived cell lines and the A172 glioma cell line. Cells were incubated in the presence of increasing amounts of neutralizing antibodies to SCF (R&D Systems) or suramin (Calbiochem) in serum-free media for 3 days and proliferation expressed as in Figure 3 . Suramin inhibits the proliferation of the A172 cell line, but has no signi®cant eect on the proliferation of NF1-derived Schwann cell lines shown). In order to evaluate the possibility of an autocrine loop involving other growth factors and their receptors, cells were cultured in the presence of suramin, a blocker of growth factor/growth factor receptor interactions with a broad range of action. Suramin was very eective in blocking the proliferation of the A172 cell line (Figure 4b ), which is known to be largely dependent upon an autocrine loop involving PDGF/PDGF receptors (Fleming et al., 1992; Sato and Nitta, 1994) . Suramin did not decrease the growth of the NFS-derived Schwann cell lines. A limited increase in cell number compared to untreated cells was observed at low suramin concentrations (Figure 4b) .
In order to directly test if Kit can assume a role in Schwann cell hyperplasia, the eect of SCF on proliferation of the four Schwann cell lines was evaluated (Figure 5a ). Cells were cultured in the presence of 20 ng/ml SCF. After 4 days in culture the number of cells was evaluated relative to untreated cells. SCF produced a signi®cant increase in the number of ST88-14 cells. The response of the T265-2c cell line, which expressed intermediate levels of Kit, to SCF was less robust but signi®cant. In contrast, SCF was a poor mitogen for the NF1T and STS-26T cell lines. ST88-14 cells and NF1T cells were cultured over longer periods of time in the presence of increasing concentrations of SCF. SCF stimulated the proliferation of the ST88-14 cells in a dose-dependent manner, leading to a twofold increase in cell number over 10 days, relative to untreated cells ( Figure 5b) ; the eect was maximal at 10 ng/ml and less at 100 ng/ml. SCF did not signi®cantly stimulate the proliferation of the NF1T cell line (Figure 5c ).
In this report, we have shown that the protooncogene Kit is highly expressed in NFS-derived cells de®cient in neuro®bromin, but expressed at low levels in primary Schwann cells or malignant Schwann cells with normal levels of neuro®bromin expression. Kit expressed by the NFS-Schwann cells is functional and SCF stimulates the NFS-derived Schwann cells to proliferate. These results indicate that high expression of Kit in NFS-derived Schwann cells may be associated with the NF1-phenotype (i.e. neurofibromin de®ciency) and that SCF stimulation of Schwann cell proliferation can contribute to the hyperplastic phenotype that leads to Schwann cell tumor formation in NF1 patients.
Kit is expressed at low levels in adult human Schwann cells (Ryan et al., 1994 , TJ Lopez and GH DeVries, unpublished data), but is expressed at high levels in the ST88-14 and T265-2c cell lines, two NFSderived Schwann cell lines. Kit expression appears to be speci®cally associated with the NF1 phenotype and not, more generally, with a transformed phenotype. Indeed, the STS-26T cell line, a schwannoma-derived cell line from a patient without NF1, and an immortalized rat Schwann cell line (Ryan et al., 1994) display very limited expression of Kit. The observation that the NF1T cell line, which is a NFSderived cell line, does not display high levels of Kit could appear in contradiction with this hypothesis. But examination of neuro®bromin expression in the dierent cell lines shows that the NF1T cell line, contrary to the other NFS-derived lines, expresses levels of neuro®bromin comparable to normal cells. It has been shown that Schwann cell dierentiation is associated with increased expression of neuro®bromin (Gutmann et al., 1993) . Recent studies from our laboratory show that among the four Schwann cell lines described in this study, the NF1T cell line bears the most resemblance to normal Schwann cells. The NF1T cell line maintains a bipolar morphology characteristic of Schwann cells, has the highest level of CNPase activity (CNPase is a biochemical marker of myelin) and retains its ability to preferentially associate with axons (Klein and DeVries, submitted for publication). Because of its more dierentiated phenotype, it is not surprising to observe the expression of neuro®bromin in the NF1T cell line. However, we cannot exclude the possibility that neuro®bromin expressed in the NF1T cells may present subtle mutations that cannot be resolved using polyacrylamide gel electrophoresis. A recent study described that neuro®bromas, with normal levels of neuro®bromin, displayed intermediate levels of Ras-GTP, compared to neuro®brosarcomas (Guha et al., 1996) . This intermediate phenotype may be insucient to induce an increase in Kit expression. Thus, although only a limited number of NF1-cell lines have been tested so far, our data indicate that Kit is overexpressed in NFS-derived Schwann cells showing a reduction in neuro®bromin. However, a direct relationship between the decrease in neuro®bromin and the upregulation of Kit expression still needs to be demonstrated.
Kit expressed in the NFS-derived cell lines is constitutively tyrosyl-phosphorylated, possibly due to its interaction with endogenously produced SCF. We were able to block the proliferation of the NFS-derived Schwann cell lines, using low doses of an inhibitor selective for the PDGF-receptor subclass of tyrosine kinase receptor. The growth of the NFS-cell lines was not signi®cantly aected by the addition of suramin to the media. Suramin, a polyanionic drug, is thought to interfere with the binding of the growth factors to low anity, heparan-sulfate proteoglycan receptors. Suramin has been used in many instances to block autocrine growth loops due to PDGF, ®broblast growth factor and insulin-like growth factor, which are all well known mitogens for Schwann cells. It has been shown recently that suramin inhibits the responsiveness of Schwann cells to glial growth factor, the most potent Schwann cell mitogen (Sudhalter et al., 1996) . Because of the lack of eect of suramin on the proliferation of the NFS-derived cells, it is unlikely that any of these growth factors contribute to the autocrine growth of the NFS-derived cells. We were unable to interrupt the NFS-derived Schwann cell proliferation using antibodies speci®c for Kit and SCF. One possibility is that the SCF/Kit interaction takes place intracellularly. Even though the actual mechanism remains unclear, it has been shown that a PDGF/PDGF receptor autocrine growth loop can take place even when PDGF was modi®ed so that it could no longer be secreted extracellularly (Keating and Williams, 1988) . It is also believed that a large part of the interactions between SCF and Kit in breast carcinoma cell lines and tumors occurs intracellularly (Hines et al., 1995) . It is also possible that the 80 kDa protein represents a truncated, constitutively active form of Kit. Finally, it has recently been shown that, in human astrocytes, high levels of Kit expression in the absence of its ligand resulted in apoptotic cell death (He et al., 1997) .
Experiments evaluating the eect of SCF on the Schwann cell lines show unambiguously that Kit activation stimulates the proliferation of the NFSderived cells. However, the mitogenicity of SCF for the NFS-derived lines, and for the T265-2c cell line in particular, is only moderate. This could be explained by the lower levels of Kit expression of this cell line (relative to the ST88-14) and the fact that a signi®cant proportion of Kit may be interacting with endogenous SCF, limiting the response elicited by exogenous SCF. Similar observations were reported in breast carcinoma cells, co-expressing SCF and Kit; only high levels of Kit expression allow a growth response to an excess of SCF (Hines et al., 1995) . The dose required to elicit maximal cell growth in our study is relatively low, possibly due to the fact that Kit binding sites are already partially occupied by endogenous SCF. In the hemopoietic system, SCF alone has a very modest eect on the proliferation of early hemopoietic precursors but it markedly potentiates the eect of other growth factors, such as interleukin 3, erythropoietin, GM-CSF and G-CSF (McNiece et al., 1991) . Thus, it is possible that SCF may act in cooperation with other factors to stimulate NFS-derived Schwann cell proliferation. In that context, it will be interesting to test the eect of factors that increase intracellular cyclic AMP levels, as elevating cyclic AMP levels in Nf1-de®cient mouse Schwann cells results in Schwann cell hyperplasia (Kim et al., 1997) .
We have shown that Kit is expressed at high levels in NFS-derived cells displaying decreased neurofibromin expression and that Kit activation by SCF can induce a proliferative response in NFS-derived cells. In the tumors, Kit may be activated by endogenous SCF produced by the Schwann cell-like cells themselves. However, in vivo, exogenous sources of SCF such as the ®broblasts present in the tumors and circulating SCF from the serum can contribute to Kit activation. The respective contributions of the various sources of SCF to Schwann cell hyperplasia in the neurofibrosarcomas still need to be investigated, as does the possible involvement of co-factors, produced by other cell types present in the tumors (®broblasts, mast cells) which could potentiate SCF mitogenicity towards Schwann cells. In turn, a better understanding of the cellular mechanisms leading to the abnormal proliferation of Schwann cells in neuro®bromas and neurofibrosarcomas will allow the design of new therapeutic strategies for NF1.
